Our study findings supported most researchers' findings that HG/HL could reduce the level of autophagy, and like metformin [5], the first-line drug for the treatment of diabetes, and other drugs such as rosiglitazone and glucagon-like peptide 1 (GLP-1) [5–7], YNJ-medicated serum was shown to enhance the autophagy of INS-1 cells in the present study, which indicates that YNJ's therapeutic effect on diabetic patients is related to its enhancement of autophagy in INS-1 cells. Here, GLP1R is linked to diabetes mellitus.